title: New Oral Anticoagulants in Coronary Artery Disease.
abstract: The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guideline-based recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
authors.affiliation: First Department of Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, Heidelberg University, Germany, Theodor-Kutzer-Ufer 1-3, D- 68167 Mannheim, Germany. michael.behnes@umm.de.
authors.forename: Michael
authors.initials: M
authors.lastname: Behnes
authors.forename: Christian
authors.initials: C
authors.lastname: Fastner
authors.forename: Uzair
authors.initials: U
authors.lastname: Ansari
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Akin
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D055808:Drug Discovery; D006801:Humans; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants